Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Colorectal Neoplasms

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 61 articles:
HTML format
Text format



Single Articles


    March 2017
  1. FUCHS MA, Yuan C, Sato K, Niedzwiecki D, et al
    Predicted Vitamin D Status and Colon Cancer Recurrence and Mortality in CALGB 89803 (Alliance).
    Ann Oncol. 2017 Mar 15. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  2. PILATI C, Taieb J, Balogoun R, Marisa L, et al
    CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification.
    Ann Oncol. 2017 Feb 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  3. LONARDI S, Sobrero A, Rosati G, Di Bartolomeo M, et al
    Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
    Ann Oncol. 2017 Feb 23. doi: 10.1093.
    PubMed     Text format    


  4. LOTE H, Spiteri I, Ermini L, Vatsiou A, et al
    Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer.
    Ann Oncol. 2017 Feb 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  5. SANTINI D, Vincenzi B, Addeo R, Garufi C, et al
    Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
    Ann Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format    


  6. DIENSTMANN R, Mason MJ, Sinicrope FA, Phipps AI, et al
    Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.
    Ann Oncol. 2017 Feb 9. doi: 10.1093.
    PubMed     Text format    


  7. SUENAGA M, Schirripa M, Cao S, Zhang W, et al
    Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
    Ann Oncol. 2017 Feb 9. doi: 10.1093.
    PubMed     Text format    


    January 2017
  8. AUCLIN E, Zaanan A, Vernerey D, Douard R, et al
    Subgroups and Prognostication in Stage III Colon Cancer: Future Perspectives for Adjuvant Therapy.
    Ann Oncol. 2017 Jan 27. pii: mdx030. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2016
  9. TAIEB J, Balogoun R, Le Malicot K, Tabernero J, et al
    Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
    Ann Oncol. 2016 Dec 28. pii: mdw687. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. SCHUURHUIZEN CS, Braamse AM, Konings IR, Sprangers MA, et al
    Does severe toxicity affect global quality of life in patients with metastatic colorectal cancer during palliative systemic treatment? A systematic review.
    Ann Oncol. 2016 Dec 19. pii: mdw617. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. SELIGMANN JF, Fisher D, Smith CG, Richman SD, et al
    Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    November 2016
  12. PIETRANTONIO F, Miceli R, Rimassa L, Lonardi S, et al
    Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  13. SWETS M, Breugom AJ, Gelderblom H, van de Velde CJ, et al
    Should rectal cancer located 10-15cm from the anal verge be defined as colon cancer.
    Ann Oncol. 2016.
    PubMed     Text format    


    October 2016
  14. QUIDDE J, Hegewisch-Becker S, Graeven U, Lerchenmuller CA, et al
    Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  15. MOORE M, Gill S, Asmis T, Berry S, et al
    Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  16. DEENEN MJ, Meulendijks D
    Recommendation on testing for dihydropyrimidine dehydrogenase deficiency in the ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
    Ann Oncol. 2016.
    PubMed     Text format    


    September 2016

  17. appendix 5: Metastatic colorectal cancer (2): eUpdate published online August 2016 (www.esmo.org/Guidelines/Gastrointestinal-Cancers).
    Ann Oncol. 2016;27.
    PubMed     Text format    



  18. appendix 4: Metastatic colorectal cancer (1): eUpdate published online September 2016 (www.esmo.org/Guidelines/Gastrointestinal-Cancers).
    Ann Oncol. 2016;27.
    PubMed     Text format    


    August 2016
  19. LONARDI S, Sobrero A, Rosati G, Di Bartolomeo M, et al
    Phase III trial comparing 3 to 6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  20. IMAOKA H, Toiyama Y, Fujikawa H, Hiro J, et al
    Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  21. VARDY JL, Dhillon HM, Pond GR, Renton C, et al
    Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  22. MEI Z, Duan C, Li C, Cui L, et al
    Prognostic role of tumor PIK3CAmutation in colorectal cancer: a systematic review and meta-analysis.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  23. VAN CUTSEM E, Cervantes A, Adam R, Sobrero A, et al
    ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    June 2016
  24. MODEST DP, Ricard I, Heinemann V, Hegewisch-Becker S, et al
    Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants - pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  25. SOBRERO A
    A tribute to biologics in advanced colorectal cancer treatment.
    Ann Oncol. 2016.
    PubMed     Text format    


    May 2016
  26. MICHL M, Stintzing S, Fischer von Weikersthal L, Decker T, et al
    CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  27. REN HG, Luu HN, Cai H, Xiang YB, et al
    Oral health and risk of colorectal cancer: results from three cohort studies and a meta-analysis.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  28. LUO HY, Xu RH
    Reply to "Safety profile of capecitabine as maintenance treatment after XELOX or FOLFOX in metastatic colorectal cancer patients" by C. Cremolini et al.
    Ann Oncol. 2016.
    PubMed     Text format    


  29. YAMAZAKI K, Nagase M, Tamagawa H, Ueda S, et al
    Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  30. CREMOLINI C, Moretto R, Masi G, Falcone A, et al
    Safety profile of capecitabine as maintenance treatment after XELOX or FOLFOX in metastatic colorectal cancer patients.
    Ann Oncol. 2016.
    PubMed     Text format    


  31. SARTORE-BIANCHI A, Loupakis F, Argiles G, Prager GW, et al
    Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the lab.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  32. HERNANDEZ J, Molins L, Fibla JJ, Heras F, et al
    Role of major resection in pulmonary metastasectomy for colorectal cancer in the Spanish prospective multicenter study (GECMP-CCR).
    Ann Oncol. 2016;27:850-5.
    PubMed     Text format     Abstract available


    April 2016
  33. FOLPRECHT G, Pericay C, Saunders MP, Thomas A, et al
    Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first line treatment of patients with metastatic colorectal cancer - the AFFIRM study.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  34. LUCHINI C, Nottegar A, Pea A, Solmi M, et al
    Significance of the prognostic stratification of extranodal extension in colorectal cancer.
    Ann Oncol. 2016.
    PubMed     Text format    


    March 2016
  35. CIARDIELLO F, Normanno N, Martinelli E, Troiani T, et al
    Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase 2 trial of FOLFOX plus cetuximab versus FOLFOX.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  36. LUO HY, Li YH, Wang W, Wang ZQ, et al
    Single-Agent Capecitabine as Maintenance Therapy After Induction of XELOX (or FOLFOX) in First-Line Treatment of Metastatic Colorectal Cancer: Randomized clinical trial of efficacy and safety.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    February 2016
  37. AMATU A, Barault L, Moutinho C, Cassingena A, et al
    Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  38. JONES MR, Schrader KA, Shen Y, Pleasance E, et al
    Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  39. OVERMAN MJ, Morris V, Kee B, Fogelman D, et al
    Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  40. KANAI M, Kawaguchi T, Kotaka M, Shinozaki K, et al
    Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial).
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  41. CREMOLINI C, Loupakis F, Masi G, Lonardi S, et al
    FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  42. PIGNATTI F, Martinalbo J, Jonsson B, Foggi P, et al
    Reply to "Number-Needed-To-Treat for pricing costly anti-cancer drugs. The example of Regorafenib in metastatic colorectal cancer." by F. Graziano et al.
    Ann Oncol. 2016.
    PubMed     Text format    


  43. ROSATI G, Ambrosini G, Barni S, Andreoni B, et al
    A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma.
    Ann Oncol. 2016;27:274-80.
    PubMed     Text format     Abstract available


    January 2016
  44. QIN X, Huang Q
    Prognostic impact of extracapsular lymph node involvement in colorectal cancer.
    Ann Oncol. 2016.
    PubMed     Text format    


  45. GRAZIANO F, Rulli E, Biagioli E, Catalano V, et al
    Number-Needed-To-Treat for pricing costly anti-cancer drugs. The example of Regorafenib in metastatic colorectal cancer.
    Ann Oncol. 2016.
    PubMed     Text format    


    December 2015
  46. TREASURE T, Macbeth F
    The GILDA trial finds no survival benefit from intensified screening after primary resection of colorectal cancer: the PulMiCC trial tests the survival benefit of pulmonary metastasectomy for detected asymptomatic lung metastases.
    Ann Oncol. 2015.
    PubMed     Text format    


    November 2015
  47. FRAMPTON M, Law P, Litchfield K, Morris EJ, et al
    Implications of polygenic risk for personalised colorectal cancer screening.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


  48. LEVI FA, Boige V, Hebbar M, Smith D, et al
    Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.
    Ann Oncol. 2015.
    PubMed     Text format     Abstract available


  49. KANYILMAZ G, Koc M, Aktan M
    Adjuvant chemotherapy after preoperative chemoradiotherapy for rectal cancer.
    Ann Oncol. 2015;26:2352.
    PubMed     Text format    


    April 2015
  50. MORELLI MP, Overman MJ, Dasari A, Kazmi SM, et al
    Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.
    Ann Oncol. 2015;26:731-6.
    PubMed     Text format     Abstract available


  51. CASTELLS A
    Postoperative surveillance in nonmetastatic colorectal cancer patients: yes, but...
    Ann Oncol. 2015;26:615-7.
    PubMed     Text format    


  52. KOEBERLE D, Betticher DC, von Moos R, Dietrich D, et al
    Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).
    Ann Oncol. 2015;26:709-14.
    PubMed     Text format     Abstract available


  53. CERVANTES A, Glynne-Jones R
    Adjuvant chemotherapy for rectal cancer after preoperative radiation or chemoradiation: one size does not fit all.
    Ann Oncol. 2015;26:617-9.
    PubMed     Text format    


  54. MASI G, Salvatore L, Boni L, Loupakis F, et al
    Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.
    Ann Oncol. 2015;26:724-30.
    PubMed     Text format     Abstract available


  55. HALLER DG, O'Connell MJ, Cartwright TH, Twelves CJ, et al
    Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials.
    Ann Oncol. 2015;26:715-24.
    PubMed     Text format     Abstract available


  56. GRUENBERGER T, Bridgewater J, Chau I, Garcia Alfonso P, et al
    Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
    Ann Oncol. 2015;26:702-8.
    PubMed     Text format     Abstract available


  57. BREUGOM AJ, van Gijn W, Muller EW, Berglund A, et al
    Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial.
    Ann Oncol. 2015;26:696-701.
    PubMed     Text format     Abstract available


  58. PITA-FERNANDEZ S, Alhayek-Ai M, Gonzalez-Martin C, Lopez-Calvino B, et al
    Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis.
    Ann Oncol. 2015;26:644-56.
    PubMed     Text format     Abstract available


    February 2015
  59. GNANT M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, et al
    Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
    Ann Oncol. 2015;26:313-20.
    PubMed     Text format     Abstract available


  60. HEBBAR M, Chibaudel B, Andre T, Mineur L, et al
    FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomi
    Ann Oncol. 2015;26:340-7.
    PubMed     Text format     Abstract available


    December 2014
  61. SCHOFFSKI P, Besse B, Gauler T, de Jonge MJ, et al
    Efficacy and safety of biweekly intravenous administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small cell and non-small cell l
    Ann Oncol. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: